RAGE and TLR4 differentially regulate airway hyperresponsiveness: implications for COPD.
Allam, VSRR
Faiz, A
Lam, M
Rathnayake, SNH
Ditz, B
Pouwels, SD
Brandsma, C-A
Timens, W
Hiemstra, PS
Tew, GW
Neighbors, M
Grimbaldeston, M
van den Berge, M
Donnelly, S
Phipps, S
Bourke, JE
Sukkar, MB
- Publisher:
- John Wiley and Sons
- Publication Type:
- Journal Article
- Citation:
- Allergy, 2021, 76, (4), pp. 1123-1135
- Issue Date:
- 2021-01-01
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
all.14563.pdf | 1.1 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Allam, VSRR | |
dc.contributor.author |
Faiz, A https://orcid.org/0000-0003-1740-3538 |
|
dc.contributor.author | Lam, M | |
dc.contributor.author | Rathnayake, SNH | |
dc.contributor.author | Ditz, B | |
dc.contributor.author | Pouwels, SD | |
dc.contributor.author | Brandsma, C-A | |
dc.contributor.author | Timens, W | |
dc.contributor.author | Hiemstra, PS | |
dc.contributor.author | Tew, GW | |
dc.contributor.author | Neighbors, M | |
dc.contributor.author | Grimbaldeston, M | |
dc.contributor.author | van den Berge, M | |
dc.contributor.author |
Donnelly, S https://orcid.org/0000-0003-2005-3698 |
|
dc.contributor.author | Phipps, S | |
dc.contributor.author | Bourke, JE | |
dc.contributor.author | Sukkar, MB | |
dc.date.accessioned | 2021-12-06T03:19:30Z | |
dc.date.available | 2020-07-14 | |
dc.date.available | 2021-12-06T03:19:30Z | |
dc.date.issued | 2021-01-01 | |
dc.identifier.citation | Allergy, 2021, 76, (4), pp. 1123-1135 | |
dc.identifier.issn | 0105-4538 | |
dc.identifier.issn | 1398-9995 | |
dc.identifier.uri | http://hdl.handle.net/10453/152138 | |
dc.description.abstract | BACKGROUND:The receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4) are implicated in COPD. Although these receptors share common ligands and signaling pathways, it is not known whether they act in concert to drive pathological processes in COPD. We examined the impact of RAGE and/or TLR4 gene deficiency in a mouse model of COPD and also determined whether expression of these receptors correlates with airway neutrophilia and airway hyperreactivity (AHR) in COPD patients. METHODS:We measured airway inflammation and AHR in wild-type, RAGE-/- , TLR4-/- and TLR4-/- RAGE-/- mice following acute exposure to cigarette smoke (CS). We also examined the impact of smoking status on AGER (encodes RAGE) and TLR4 bronchial gene expression in patients with and without COPD. Finally, we determined whether expression of these receptors correlates with airway neutrophilia and AHR in COPD patients. RESULTS:RAGE-/- mice were protected against CS-induced neutrophilia and AHR. In contrast, TLR4-/- mice were not protected against CS-induced neutrophilia and had more severe CS-induced AHR. TLR4-/- RAGE-/- mice were not protected against CS-induced neutrophilia but were partially protected against CS-induced mediator release and AHR. Current smoking was associated with significantly lower AGER and TLR4 expression irrespective of COPD status, possibly reflecting negative feedback regulation. However, consistent with preclinical findings, AGER expression correlated with higher sputum neutrophil counts and more severe AHR in COPD patients. TLR4 expression did not correlate with neutrophilic inflammation or AHR. CONCLUSIONS:Inhibition of RAGE but not TLR4 signalling may protect against airway neutrophilia and AHR in COPD. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | John Wiley and Sons | |
dc.relation.ispartof | Allergy | |
dc.relation.isbasedon | 10.1111/all.14563 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1107 Immunology | |
dc.subject.classification | Allergy | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.subject.mesh | Respiratory Hypersensitivity | |
dc.subject.mesh | Mitogen-Activated Protein Kinases | |
dc.subject.mesh | Antigens, Neoplasm | |
dc.subject.mesh | Smoking | |
dc.subject.mesh | Toll-Like Receptor 4 | |
dc.subject.mesh | Receptor for Advanced Glycation End Products | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antigens, Neoplasm | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Mitogen-Activated Protein Kinases | |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | |
dc.subject.mesh | Receptor for Advanced Glycation End Products | |
dc.subject.mesh | Respiratory Hypersensitivity | |
dc.subject.mesh | Smoking | |
dc.subject.mesh | Toll-Like Receptor 4 | |
dc.title | RAGE and TLR4 differentially regulate airway hyperresponsiveness: implications for COPD. | |
dc.type | Journal Article | |
utslib.citation.volume | 76 | |
utslib.location.activity | Denmark | |
utslib.for | 1107 Immunology | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Students | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | closed_access | * |
pubs.consider-herdc | true | |
dc.date.updated | 2021-12-06T03:19:28Z | |
pubs.issue | 4 | |
pubs.publication-status | Published | |
pubs.volume | 76 | |
utslib.citation.issue | 4 |
Abstract:
BACKGROUND:The receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4) are implicated in COPD. Although these receptors share common ligands and signaling pathways, it is not known whether they act in concert to drive pathological processes in COPD. We examined the impact of RAGE and/or TLR4 gene deficiency in a mouse model of COPD and also determined whether expression of these receptors correlates with airway neutrophilia and airway hyperreactivity (AHR) in COPD patients. METHODS:We measured airway inflammation and AHR in wild-type, RAGE-/- , TLR4-/- and TLR4-/- RAGE-/- mice following acute exposure to cigarette smoke (CS). We also examined the impact of smoking status on AGER (encodes RAGE) and TLR4 bronchial gene expression in patients with and without COPD. Finally, we determined whether expression of these receptors correlates with airway neutrophilia and AHR in COPD patients. RESULTS:RAGE-/- mice were protected against CS-induced neutrophilia and AHR. In contrast, TLR4-/- mice were not protected against CS-induced neutrophilia and had more severe CS-induced AHR. TLR4-/- RAGE-/- mice were not protected against CS-induced neutrophilia but were partially protected against CS-induced mediator release and AHR. Current smoking was associated with significantly lower AGER and TLR4 expression irrespective of COPD status, possibly reflecting negative feedback regulation. However, consistent with preclinical findings, AGER expression correlated with higher sputum neutrophil counts and more severe AHR in COPD patients. TLR4 expression did not correlate with neutrophilic inflammation or AHR. CONCLUSIONS:Inhibition of RAGE but not TLR4 signalling may protect against airway neutrophilia and AHR in COPD.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph